News & Analysis

Biotechnology & Biopharmaceutical Industry News, Analysis and Commentary.

February 4, 2019

Cell & Gene Therapy: Increasing Demand for Viral Vectors Drives Biomanufacturing Innovation & CDMO Investment

[vc_row][vc_column][vc_column_text] Cell and gene therapies (CGTs) offer an unprecedented opportunity to treat diseases for which existing interventions are inadequate, potentially offering cures for previously terminal illnesses. […]
October 24, 2018

RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam’s Thirty Year Journey to First Approval

[vc_row][vc_column][vc_column_text]   In August 2018, the FDA & European Commission announced the approval of Alnylam Pharmaceutical’s ONPATTRO, a first-of-its-kind RNA interference (RNAi) therapeutic. Evolution Executive’s latest […]
October 10, 2018

Global Drug Development IPOs: 26 Companies Raise $3.18B in Q3 as First Pre-Revenue Biotechs List on HKEX

[vc_row][vc_column][vc_column_text] The Drug Development IPO market enjoyed a strong third quarter, with over $3.18B raised by 26 companies across the globe, bringing the year-to-date total up […]
August 10, 2018

Democratising DNA: 23andMe & GSK Collaboration Highlights Data Quality & Privacy Concerns; Can Blockchain Offer a Disruptive Solution?

[vc_row][vc_column][vc_column_text] Personal genomics company 23andMe recently entered a four-year $500M collaborative agreement with major pharmaceutical company GlaxoSmithKline. The deal gives GSK access to the genetic data […]